Lupin's generic Onfi gets FDA approval
Lupin has received the Food and Drug Administration’s blessing for Clobazam oral suspension, 2.5 mg/mL.
The product is a generic version of Lundbeck’s Onfi oral suspension, 2.5 mg/mL.
It is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in patients 2 years of age or older.
Clobazam oral suspension, 2.5 mg/mL had a market value of approximately $260.2 million, according to IQVIA September 2018 data.
The product is a generic version of Lundbeck’s Onfi oral suspension, 2.5 mg/mL.
It is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in patients 2 years of age or older.
Clobazam oral suspension, 2.5 mg/mL had a market value of approximately $260.2 million, according to IQVIA September 2018 data.